55 Results for "

human PPAR-α

" in MedChemExpress (MCE) Product Catalog:
Products (55)

55 Results for "human PPAR-α" in MCE Product Catalog:

  • Targets Recommended:
38
38 Publications Verification
Cat. No.: HY-16995
CAS No.: 50892-23-4
Synonyms: Wy-14643
Target:  

PPAR

Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.
loading...
    loading...
36
36 Cited Publications
Cat. No.: HY-17356
CAS No.: 49562-28-9
Research Areas:  

Cardiovascular Disease Cancer

Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
loading...
    loading...
25
25 Cited Publications
Cat. No.: HY-13861
CAS No.: 265129-71-3
Purity:  99.45%
Target:  

PPAR

Research Areas:  

Cardiovascular Disease

GW7647 is a potent PPARα agonist, with EC50s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-13928
CAS No.: 317318-84-6
Purity:  99.94%
Synonyms: GW610742
GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-B0637
CAS No.: 41859-67-0
Synonyms: BM15075
Target:  

PPAR

Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-14166
CAS No.: 118414-82-7
Purity:  99.87%
Synonyms: L 663536
Research Areas:  

Cancer

MK-886 (L 663536) is a potent, cell-permeable and orally active FLAP (IC50 of 30 nM) and leukotriene biosynthesis (IC50s of 3 nM and 1.1 μM in intact leukocytes and human whole blood, respectively) inhibitor. MK-886 is also a non-competitive PPARα antagonist and can induce apoptosis .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-114263
CAS No.: 1454925-59-7
Purity:  99.07%
Target:  

PPAR

Research Areas:  

Cancer

NXT629 is a potent, selective, and competitive PPAR-α antagonist, with an IC50 of 77 nM for human PPARα, shows high selectivity over other nuclear hormone receptor, such as PPARδ, PPARγ, ERβ, GR and TRβ, IC50s are 6.0, 15, 15.2, 32.5 and >100 μM, respectively . NXT629 has potent anti-tumor activity and inhibits experimental metastasis of cancer cell in animal models .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-B0287
CAS No.: 637-07-0
Target:  

PPAR

Research Areas:  

Metabolic Disease

Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ~500 μM for murine PPARα and PPARγ, and 55 μM, ~500 μM for human PPARα and PPARγ, respectively.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-10678
CAS No.: 1000998-59-3
Purity:  99.31%
Target:  

PPAR

Research Areas:  

Cardiovascular Disease

BMS-687453 is a potent and selective PPARα agonist, with an EC50 and IC50 of 10 nM and 260 nM for human PPARα and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0515
CAS No.: 945619-74-9
Ophiopogonin D can be isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C29 steroidal glycoside. Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca 2+ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D can inhibit isteoclastic differentiation in RAW264.7 cells. Ophiopogonin D has protective effect as an antioxidant in H2O2-induced endothelial injury. Ophiopogonin D blocks ERK signaling cascades. Ophiopogonin D alleviates high-fat diet-induced metabolic syndrome and changes the structure of gut microbiota in mice. Ophiopogonin D has been used against inflammatory, metabolic and cardiovascular diseases .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N1990
CAS No.: 94987-08-3
Gypenoside XLIX is a multifunctional bioactive compound that can be isolated from Gynostemma pentaphyllum, with a Ka value of 1.58 μM for its binding to SIRT1. Gypenoside XLIX acts as a PPAR-α agonist. It inhibits the activation of TLR4-mediated NF-κB signaling pathway by activating the Sirt1/Nrf2 signaling pathway, reduces ROS accumulation, and alleviates hepatic inflammatory injury in mice with sepsis-induced liver disease. Gypenoside XLIX targets SIRT1 to block YAP-NLRP3 activation and improve sepsis-induced cardiomyopathy. Gypenoside XLIX inhibits apoptosis (Apoptosis), pyroptosis (Pyroptosis), autophagy (Autophagy), lipid peroxidation, pro-inflammatory cytokines and anti-inflammatory cytokines. Gypenoside XLIX alleviates sepsis-induced splenic injury by inhibiting inflammation and oxidative stress, and mitigates sepsis-associated encephalopathy by targeting PPAR-α. Gypenoside XLIX prevents acute kidney injury by inhibiting IGFBP7/IGF1R-mediated programmed cell death and inflammation. Gypenoside XLIX inhibits the expression and activity of vascular cell adhesion molecule-1 in cytokine-induced human endothelial cells. Gypenoside XLIX is applicable to research related to acute liver injury, lung injury, cardiomyopathy, acute splenic injury, sepsis-associated encephalopathy, acute kidney injury, atherosclerosis and chronic inflammation .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P7996
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: PPARA; HPPAR; Prev. PPAR; PPAR-Alpha; Peroxisome Proliferator-Activated Receptor Alpha; Alternative Protein PPARA; NR1C1; PPARalpha; Nuclear Receptor Subfamily 1 Group C Member 1; Peroxisome Proliferator Activated Receptor Alpha; Peroxisome Proliferative Activated Receptor, Alpha
Species:  
Human
Source:  
E. coli
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W081067
CAS No.: 13252-13-6
Synonyms: HFPO-DA
Target:  

PPAR

Research Areas:  

Infection

Perfluoro (2-methyl-3-oxahexanoic) acid (HFPO-DA) is an orally active PPARα agonist with an EC50 of 2.1 μM for human PPARα. Perfluoro (2-methyl-3-oxahexanoic) acid induces peroxisome proliferation and increases the levels of proinflammatory mediators. It impairs intestinal barrier function and disrupts cecal flora balance. Perfluoro (2-methyl-3-oxahexanoic) acid is applicable to research related to developmental toxicity, hepatotoxicity and intestinal toxicity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-121538
CAS No.: 479413-68-8
Purity:  ≥98.0%
Target:  

Epoxide Hydrolase PPAR

Research Areas:  

Cardiovascular Disease

CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-121538A
Target:  

Epoxide Hydrolase PPAR

Research Areas:  

Cardiovascular Disease

CUDA disodium is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA disodium selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA disodium may be valuable for the research of cardiovascular disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-117196
CAS No.: 247923-29-1
Purity:  99.6%
Target:  

PPAR

GW9578 is a subtype-selective PPARα agonist (EC50s of 5 and 50 nM for murine and human PPAR-α) with potent lipid-lowering activity .
loading...
    loading...
Cat. No.: HY-17444
CAS No.: 251565-85-2
Target:  

PPAR

Research Areas:  

Metabolic Disease Cancer

Tesaglitazar is a dual-target PPARα/γ agonist with an EC50 of 13.4 μM for rat PPARα and 3.6 μM for human PPARα. Tesaglitazar affects lipid and glucose metabolism by activating PPARα and PPARγ receptors, and has the potential to improve blood sugar and relieve pain. Tesaglitazar can be used to induce in vivo tumor models and can be used in the study of type 2 diabetes, dyslipidemia, and neuropathic pain .
loading...
    loading...
Cat. No.: HY-17445
CAS No.: 331741-94-7
Synonyms: BMS-298585
Target:  

PPAR

Muraglitazar (BMS-298585) is an orally active non-thiazolidinedione oxybenzylglycine dual-target PPARα/PPARγ agonist, with an IC50 of 0.25 μM and an EC50 of 0.32 μM against human PPARα, and an IC50 of 0.19 μM and an EC50 of 0.11 μM against human PPARγ. Muraglitazar regulates lipid homeostasis, enhances peripheral insulin sensitivity, and improves β-cell function. Muraglitazar reduces levels of blood glucose, insulin, triglycerides and free fatty acids, normalizes adiponectin and corticosterone levels, promotes cholesterol efflux, reduces hepatic lipid content, regulates body weight, prevents hyperglycemia, and improves glucose tolerance. Muraglitazar can be used in research related to type 2 diabetes and dyslipidemia .
loading...
    loading...
Cat. No.: HY-154795
CAS No.: 658701-67-8
Purity:  99.81%
Synonyms: 18α-Glycyrrhizic acid Magnesium hydrate; 18α-GA Magnesium hydrate; 18α-Licorice-saponin H2 Magnesium hydrate
Magnesium isoglycyrrhizinate hydrate (18α-Glycyrrhizic acid Magnesium hydrate; 18α-GA Magnesium hydrate; 18α-Licorice-saponin H2 Magnesium hydrate) is a derivative of glycyrrhizic acid with oral activity. Magnesium isoglycyrrhizinate hydrate exhibits antioxidant, anti-inflammatory, hepatoprotective and cardioprotective activities. Magnesium isoglycyrrhizinate hydrate protects against ethanol-induced alcoholic liver disease in rats by upregulating the expression levels of SOD, GSH, PPAR-α and CPT-1 . Magnesium isoglycyrrhizinate hydrate shows cytotoxicity against T lymphocytes and inhibits HIV-1 replication in these cells . Magnesium isoglycyrrhizinate hydrate alleviates oxidative stress by reducing the levels of ROS, Nrf2, HO-1 and p-P65, and alleviates pyroptosis by downregulating the expression levels of NLRP3, GSDMD-N, P20 and c-IL-1β. Magnesium isoglycyrrhizinate hydrate inhibits autophagy, colonic fibrosis and myocardial fibrosis, and regulates intestinal barrier integrity. Magnesium isoglycyrrhizinate hydrate can be used in research related to alcoholic liver disease, HIV-1 infection, hepatotoxicity, acute liver failure, inflammatory bowel disease and myocardial fibrosis .
loading...
    loading...
Cat. No.: HY-50665
CAS No.: 425671-29-0
Synonyms: LY-674
Target:  

PPAR

Research Areas:  

Metabolic Disease

LY518674 is a potent, selective PPARα agonist, with an EC50 of 42 nM for human PPARα. LY518674 reduces triglycerides in and increased HDL-C and is used for the treatment of atherosclerosis .
loading...
    loading...